Yantai, May 16, 2023 – Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation of China...
Yantai, May 15, 2023 – Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company&rsq...
Yantai, China, May 15, 2023—Boan Biotech is to present the results of its research on BA1302, a novel CD228-directed antibody drug conjugate (ADC) developed by the company, as a poster at the 19th Es...
Nanjing, May 12, 2023——Boan Biotech signed a strategic cooperation agreement with GenScript Biotech Corporation (hereinafter referred to as GenScript Biotech) in Nanjing, reached a cooperation on th...
Boan Biotech recently announced that the results of phase 3 clinical study for its in-house developed Denosumab Injection (BA1102), a biosimilar product for oncology indications, will presented at the...
Yantai, China, May 4, 2023 – Boan Biotech today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initi...